Core Viewpoint - Dogwood Therapeutics, Inc. has entered into a securities purchase agreement for up to approximately $12.5 million in gross proceeds through a registered direct offering and a concurrent private placement, aimed at advancing the development of its non-opioid medicines for pain and neuropathy treatment [1][3] Group 1: Offerings Details - The offerings consist of the issuance of 4,386,037 shares of common stock and warrants to purchase an equal number of shares, priced at $2.85 per share [1][2] - The registered offering includes 2,338,948 shares of common stock, while the private offering includes pre-funded warrants for 2,047,089 shares and warrants for 4,386,037 shares [2] Group 2: Use of Proceeds - The net proceeds from the offerings will be utilized to advance the clinical development of Halneuron® and for working capital and general corporate purposes [3][4] - The company aims to support the ongoing Phase 2b final data readout for Halneuron® and pursue strategic opportunities to enhance its research portfolio [3] Group 3: Company Overview - Dogwood Therapeutics is focused on developing new non-opioid medicines for pain and neuropathic disorders, with its lead product candidate Halneuron® currently in Phase 2b development for chemotherapy-induced neuropathic pain [8] - Halneuron® has received fast track designation from the FDA, and the company also has another candidate, SP16 IV, which is set to enter a Phase 1b trial funded by the National Cancer Institute [8]
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development